161 related articles for article (PubMed ID: 14567253)
21. [Clinical experience of levofloxacin in community acquired pneumonia].
Arancibia F; Maldonado A; Torres A
Enferm Infecc Microbiol Clin; 1999; 17 Suppl 1():14-8. PubMed ID: 10563105
[No Abstract] [Full Text] [Related]
22. Sparfloxacin versus clarithromycin in the treatment of community-acquired pneumonia.
Ramirez J; Unowsky J; Talbot GH; Zhang H; Townsend L
Clin Ther; 1999 Jan; 21(1):103-17. PubMed ID: 10090428
[TBL] [Abstract][Full Text] [Related]
23. Community acquired pneumonia.
Loeb M
Clin Evid; 2002 Dec; (8):1546-57. PubMed ID: 12603953
[No Abstract] [Full Text] [Related]
24. [The place of the new quinolones in the guidelines on the treatment of community-acquired pneumonia].
Dorca J
Arch Bronconeumol; 1999 May; 35 Suppl 3():77-80. PubMed ID: 10410230
[No Abstract] [Full Text] [Related]
25. Clinical effects and bronchoalveolar transfer of levofloxacin in patients with community-acquired pneumonia.
Lin Y; Su W; Xu Z; Bai Y
Chin Med J (Engl); 2001 Feb; 114(2):212-3. PubMed ID: 11780213
[No Abstract] [Full Text] [Related]
26. Efficacy and safety of high dose intravenous ciprofloxacin in the treatment of bacterial pneumonia. Italian Ciprofloxacin Study Group.
Periti P; Mazzei T; Curti ME
Int J Antimicrob Agents; 1998 Aug; 10(3):215-22. PubMed ID: 9832282
[TBL] [Abstract][Full Text] [Related]
27. [Switch therapy for community acquired pneumonia].
Aoshima M
Nihon Rinsho; 2007 Feb; 65 Suppl 2 Pt. 1():326-30. PubMed ID: 17455640
[No Abstract] [Full Text] [Related]
28. [New quinolones for the treatment of community-acquired pneumonia--pro].
Zimmerli S
Dtsch Med Wochenschr; 2003 May; 128(19):1070. PubMed ID: 12736859
[No Abstract] [Full Text] [Related]
29. When to switch therapy in patients with severe community-acquired pneumonia.
Mortensen EM; Restrepo MI; Anzueto A
Ann Intern Med; 2008 Apr; 148(8):625; author reply 625-6. PubMed ID: 18413627
[No Abstract] [Full Text] [Related]
30. Tailored interventions to improve antibiotic use for lower respiratory tract infections in hospitals: a cluster-randomized, controlled trial.
Schouten JA; Hulscher ME; Trap-Liefers J; Akkermans RP; Kullberg BJ; Grol RP; van der Meer JW
Clin Infect Dis; 2007 Apr; 44(7):931-41. PubMed ID: 17342644
[TBL] [Abstract][Full Text] [Related]
31. Effectiveness of discontinuing antibiotic treatment after three days versus eight days in mild to moderate-severe community acquired pneumonia: randomised, double blind study.
el Moussaoui R; de Borgie CA; van den Broek P; Hustinx WN; Bresser P; van den Berk GE; Poley JW; van den Berg B; Krouwels FH; Bonten MJ; Weenink C; Bossuyt PM; Speelman P; Opmeer BC; Prins JM
BMJ; 2006 Jun; 332(7554):1355. PubMed ID: 16763247
[TBL] [Abstract][Full Text] [Related]
32. [Use of trovafloxacin therapy in community-acquired pneumonia].
Luna CM; Gené RJ
Medicina (B Aires); 1999; 59 Suppl 1():31-8. PubMed ID: 10436552
[TBL] [Abstract][Full Text] [Related]
33. [New quinolones for the treatment of community-acquired pneumonia--contra].
Egger M
Dtsch Med Wochenschr; 2003 May; 128(19):1071. PubMed ID: 12736860
[No Abstract] [Full Text] [Related]
34. Community acquired pneumonia.
Loeb M
Clin Evid; 2002 Jun; (7):1358-68. PubMed ID: 12230751
[No Abstract] [Full Text] [Related]
35. Clinical and economic evaluation of subsequent infection following intravenous ciprofloxacin or imipenem therapy in hospitalized patients with severe pneumonia.
Caldwell JW; Singh S; Johnson RH
J Antimicrob Chemother; 1999 Mar; 43 Suppl A():129-34. PubMed ID: 10225583
[TBL] [Abstract][Full Text] [Related]
36. A comparison of levofloxacin and moxifloxacin use in hospitalized community-acquired pneumonia (CAP) patients in the US: focus on length of stay.
Schein J; Janagap-Benson C; Grant R; Sikirica V; Doshi D; Olson W
Curr Med Res Opin; 2008 Mar; 24(3):895-906. PubMed ID: 18419876
[TBL] [Abstract][Full Text] [Related]
37. Sparfloxacin empirical therapy in community-acquired pneumonia. Results of a meta-analysis of 2 comparative studies.
Grassi GG; Brumpt I
Drugs; 1995; 49 Suppl 2():406-8. PubMed ID: 8549379
[No Abstract] [Full Text] [Related]
38. De-escalation versus continuation of empirical antimicrobial therapy in community-acquired pneumonia.
Yamana H; Matsui H; Tagami T; Hirashima J; Fushimi K; Yasunaga H
J Infect; 2016 Oct; 73(4):314-25. PubMed ID: 27394401
[TBL] [Abstract][Full Text] [Related]
39. Evidence based medicine: review of BTS guidelines for the management of community acquired pneumonia in adults.
Mckean MC
J Infect; 2002 Nov; 45(4):213-8. PubMed ID: 12423607
[TBL] [Abstract][Full Text] [Related]
40. Application of antimicrobial stewardship to optimise management of community acquired pneumonia.
Bosso JA; Drew RH
Int J Clin Pract; 2011 Jul; 65(7):775-83. PubMed ID: 21676120
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
